HK1195770A1 - 可比西他 的無定形固體鹽 - Google Patents
可比西他 的無定形固體鹽Info
- Publication number
- HK1195770A1 HK1195770A1 HK14109190.3A HK14109190A HK1195770A1 HK 1195770 A1 HK1195770 A1 HK 1195770A1 HK 14109190 A HK14109190 A HK 14109190A HK 1195770 A1 HK1195770 A1 HK 1195770A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cobicistat
- amorphous solid
- solid salts
- salts
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481509P | 2011-05-02 | 2011-05-02 | |
PCT/US2012/035871 WO2012151165A1 (en) | 2011-05-02 | 2012-04-30 | Amorphous solid salts |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1195770A1 true HK1195770A1 (zh) | 2014-11-21 |
Family
ID=46086061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14109190.3A HK1195770A1 (zh) | 2011-05-02 | 2014-09-11 | 可比西他 的無定形固體鹽 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140187771A1 (zh) |
EP (1) | EP2705027B1 (zh) |
JP (1) | JP2014513123A (zh) |
AU (1) | AU2012250890B2 (zh) |
CA (1) | CA2836768A1 (zh) |
ES (1) | ES2543923T3 (zh) |
HK (1) | HK1195770A1 (zh) |
PT (1) | PT2705027E (zh) |
WO (1) | WO2012151165A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013130766A1 (en) * | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
KR20150084772A (ko) * | 2012-10-23 | 2015-07-22 | 시플라 리미티드 | 약학 항레트로바이러스 조성물 |
US20160200716A1 (en) | 2012-12-26 | 2016-07-14 | Assia Chemical Industries Ltd. | Cobicistat dichlohydrate salt |
CA2931971A1 (en) * | 2013-11-29 | 2015-06-04 | Mylan Laboratories Ltd. | Amorphous cobicistat solid dispersion |
CN105732538B (zh) * | 2014-12-09 | 2018-04-13 | 杭州普晒医药科技有限公司 | 可比司他帕莫酸盐及其制备方法、药物组合物和用途 |
US10301281B2 (en) | 2014-12-11 | 2019-05-28 | Merck Sharp & Dohme Corp. | Crystal forms of a CCR5 antagonist |
RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
WO2016132378A2 (en) * | 2015-02-18 | 2016-08-25 | Msn Laboratories Private Limited | Novel process for the preparation of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2- [(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl] methyl} carbamoyl) amino] -4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate |
TW201728582A (zh) * | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
SG11201811507YA (en) | 2016-06-29 | 2019-01-30 | Kezar Life Sciences | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
IL263771B2 (en) | 2016-06-29 | 2023-09-01 | Kezar Life Sciences | Preparation process of immunoproteasome epoxytone peptide inhibitor and its precursors |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
CN110368370B (zh) * | 2018-04-12 | 2022-08-12 | 湖南千金湘江药业股份有限公司 | 一种无定形半富马酸替诺福韦二吡呋酯片及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
PT2487163T (pt) * | 2007-02-23 | 2016-11-21 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки |
-
2012
- 2012-04-30 US US14/115,079 patent/US20140187771A1/en not_active Abandoned
- 2012-04-30 PT PT127216455T patent/PT2705027E/pt unknown
- 2012-04-30 WO PCT/US2012/035871 patent/WO2012151165A1/en active Application Filing
- 2012-04-30 ES ES12721645.5T patent/ES2543923T3/es active Active
- 2012-04-30 CA CA2836768A patent/CA2836768A1/en not_active Abandoned
- 2012-04-30 AU AU2012250890A patent/AU2012250890B2/en not_active Ceased
- 2012-04-30 EP EP12721645.5A patent/EP2705027B1/en active Active
- 2012-04-30 JP JP2014509345A patent/JP2014513123A/ja active Pending
-
2014
- 2014-09-11 HK HK14109190.3A patent/HK1195770A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NZ617351A (en) | 2015-09-25 |
EP2705027A1 (en) | 2014-03-12 |
PT2705027E (pt) | 2015-09-11 |
US20140187771A1 (en) | 2014-07-03 |
WO2012151165A1 (en) | 2012-11-08 |
CA2836768A1 (en) | 2012-11-08 |
EP2705027B1 (en) | 2015-06-03 |
JP2014513123A (ja) | 2014-05-29 |
ES2543923T3 (es) | 2015-08-25 |
AU2012250890B2 (en) | 2015-05-28 |
AU2012250890A1 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286152A (en) | Modified imidazopyridinyl-aminopyridine compounds | |
EP2742051A4 (en) | AMORPHIC FORM OF DOLUTEGRAVIR | |
HK1195770A1 (zh) | 可比西他 的無定形固體鹽 | |
HK1203196A1 (zh) | 取代的苄基吡唑 | |
IL231725A0 (en) | Crystalline forms of efitinib di-maleate | |
IL229513A0 (en) | imidazopyridine compounds | |
EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
GB201001075D0 (en) | Crystalline forms | |
ZA201309220B (en) | Micelle-coated crystalline particles | |
ZA201306560B (en) | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | |
GB201304499D0 (en) | Carcainium Salts | |
IL230976A (en) | Crystalline forms of Czebitaxel | |
EP2760853A4 (en) | NEW SALTS OF ALOGLIPTIN | |
PL2578595T3 (pl) | Krystaliczna lewoizowalerylospiramycyna I | |
ZA201308160B (en) | Crystalline salts of asenapine | |
SI2448945T1 (sl) | Kristalinične oblike prasugrelovih soli | |
GB201120644D0 (en) | Herbicidal uses of compounds | |
EP2785766A4 (en) | HYDROXYPOLYAMINSALZE | |
EP2601178A4 (en) | SALTS OF LAPATINIB | |
EP2680843A4 (en) | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS | |
GB201105659D0 (en) | Compounds | |
HUP1000638A2 (en) | Process for preparation of rosuvastatin salts | |
HK1193407A1 (zh) | 吡咯烷- -基乙酸衍生物 | |
SG2014008858A (en) | Crystallization methods | |
IL230977A (en) | A crystalline form of relapaldib |